Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated solid tumors.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat
- •Nowotwór potwierdzony histologicznie z mutacją KRAS G12C
- •Zaawansowany lub przerzutowy nowotwór, którego nie można wyleczyć operacyjnie
- •Wcześniejsze leczenie innymi metodami (chemioterapia, immunoterapia lub inne leki na KRAS)
- •Dobra ogólna kondycja zdrowotna (ocena ECOG 0 lub 1)
- •Prawidłowe funkcjonowanie głównych narządów
✗ Disqualifies
- •Nowotwór pierwotny ośrodkowego systemu nerwowego
- •Aktywne przerzuty do mózgu
- •Zaburzenia wchłaniania w przewodzie pokarmowym
- •Operacja w ciągu ostatnich 28 dni lub mniejsza procedura chirurgiczna w ciągu 7 dni
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 3, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (55)
City of Hope
Duarte, United States
UC IRVINE Health
Orange, United States
UC Davis Comprehensive Cancer Center
Sacramento, United States
Stanford Cancer Institute
Stanford, United States
University of Colorado Cancer Center
Aurora, United States
Florida Cancer Specialists
Sarasota, United States
Moffitt Cancer Center and Research Institute
Tampa, United States
Community Health Network
Indianapolis, United States
Dana Farber Cancer Institute
Boston, United States
Henry Ford Cancer
Detroit, United States
START Midwest
Grand Rapids, United States
Columbia University
New York, United States
NYU Langone Health
New York, United States
Memorial Sloan Kettering Cancer Center
New York, United States
University of Oklahoma
Oklahoma City, United States
Allegheny Health Network
Pittsburgh, United States
Sarah Cannon Research Institue
Nashville, United States
Mary Crowley Cancer Research
Dallas, United States
MD Anderson
Houston, United States
NEXT Dallas
Irving, United States
NEXT Oncology San Antonio
San Antonio, United States
START Texas
San Antonio, United States
NEXT Oncology Virginia
Fairfax, United States
West Cancer Institute
Angers, France
Institut Bergonie
Bordeaux, France
Hospital Louise Pradel
Bron, France
Oscar Lambret Center of Lillle
Lille, France
Centre Leon Berard
Lyon, France
Cancer Institute of Montpellier
Montpellier, France
CHU Nantes
Nantes, France
Institute of Cancer of Strasbourg
Strasbourg, France
Universitäts Klinikum Köln
Cologne, Germany
Klinikum Esslingen GmbH
Esslingen am Neckar, Germany
Krankenhaus Bethanien Moers
Moers, Germany
Klinkum Nurnberg Paracelsus Medical Unviersity
Nuremberg, Germany
Department of Medical Oncology - Azienda Ospedaliero Uniersitaria delle Marche
Ancona, Italy
Centro Di Riferimento Oncologico
Aviano, Italy
Institute Romagnolo per lo Studio Tumori
Meldola, Italy
Niguarda Cancer Center
Milan, Italy
Istituto Nazionale Tumori IRCCS Fondazione "G. Pascale"
Naples, Italy
San Luigi Hospital
Orbassano, Italy
AUSL Romagna - S.M. delle Croci Hospital
Ravenna, Italy
Netherlands Cancer Institute Antoni van Leeuwenhoek
Amsterdam, Netherlands
Pan American Center for Oncology Trials
San Juan, Puerto Rico
START Barcelona - Hospital HM Nou Delfos
Barcelona, Spain
Institut Catala d'Oncologia Hospital
Barcelona, Spain
University Clinic of Navarra
Madrid, Spain
Fundacion MD Anderson Cancer Center
Madrid, Spain
START Madrid
Madrid, Spain
Hospital Universitario 12 de Octubre
Madrid, Spain
NEXT Oncology - Quirónsalud Madrid University Hospital
Madrid, Spain
University Clinic of Navarra
Pamplona, Spain
Hospital Universitario Virgen Macarena
Seville, Spain
La Fe University and Polytechnic Hospital
Valencia, Spain
Hospital Universitario Miguel Servet
Zaragoza, Spain
Trial contact
Revolution Medicines, Inc.
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/4/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.